{"url_path":"/sec/silo/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 OTHER INFORMATION**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1514183/0001213900-26-056079-index.html","accession_number":"0001213900-26-056079","cik":"0001514183","ticker":"SILO","issuer_name":"Silo Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1514183/0001213900-26-056079-index.html","primary_entity_key":"0001514183","primary_entity_name":"Silo Pharma, Inc."},"word_count":72,"has_tables":true,"body_markdown":"**ITEM 5. OTHER INFORMATION**\n\n  \n\n**Material changes to\nthe procedures by which security holders may recommend nominees to the board of directors.**\n\n \n\nNone.\n\n** **\n\n**Director and Officer\nTrading Arrangements**\n\n \n\nDuring our quarter ended March 31, 2026, none\nof our directors or executive officers adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule\n10b5-1 trading arrangement” as such terms are defined under Item 408 of Regulation S-K of the Exchange Act.\n\n \n\n35"}